A team of healthcare professionals, researchers and patient partners in Leeds are planning a research study about methotrexate, based upon the priorities and top concerns that have been identified by young people living with arthritis, and their families. However, before the researchers apply for funding to conduct this study, young people, parents and carers are needed to help design the study, to make it the best it can be!
If you are a young people living with juvenile idiopathic arthritis (JIA), and have experience of taking methotrexate, would you be able to attend a focus group meeting on Wednesday 29 March 2017, from 4.30 pm until 6.00 pm in Leeds? Parents, carers and family members are welcome too!
For more information, please contact Georgia on 07867 462003.
What is methotrexate?
Methotrexate is a disease-modifying anti-rheumatic drug (DMARD) that reduces the activity of the body’s immune system, which may be overactive in JIA (and in other rheumatic and musculoskeletal diseases). Many young people with JIA are treated with methotrexate.